کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
7530187 1487310 2015 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Brustkrebs-Screening in Österreich: Kennzahlen, Altersgrenzen, Screening-Intervalle und Evidenzbasis
ترجمه فارسی عنوان
غربالگری سرطان پستان در اتریش: ارقام کلیدی، محدودیت سن، فاصله بازرسی و پایه شواهد
کلمات کلیدی
اتریش، غربالگری سرطان پستان، حوادث، شواهد، ارقام کلیدی، اتریش، غربالگری سرطان پستان میزان بروز، شواهد، چهره های کلیدی،
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی سیاست های بهداشت و سلامت عمومی
چکیده انگلیسی
In January 2014, the first nationwide quality-assured breast cancer screening program addressing women aged ≥ 40 years was introduced in Austria. As part of the process of developing a patient information leaflet, the Evidence Based Medicine (EBM) Review Center of the Medical University of Graz was charged with the task of assessing the potential benefits and harms of breast cancer screening from the available evidence. Based on these results, key figures were derived for mortality, false-positive and false-negative mammography results, and overdiagnosis, considering Austria-specific incidence rates for breast cancer and breast cancer mortality. Furthermore, the current evidence regarding age limits and screening interval, which were the subjects of controversial public discussions, was analyzed. A systematic search for primary and secondary literature was performed and additional evidence was screened, e. g., evaluation reports of European breast cancer screening programs. On the basis of the available evidence and of the Austrian breast cancer mortality and incidence rates, it can be assumed that - depending on the age group - 1 to 4 breast cancer deaths can be avoided per 1,000 women screened in a structured breast cancer screening program, while the overall mortality remains unchanged. On the other hand, 150 to 200 of these 1,000 women will be affected by false-positive results and 1 to 9 women by overdiagnosis due to the structured breast cancer screening. Therefore, the overall benefit-harm balance is uncertain. If women from 40 to 44 or above 70 years of age are considered, who can also participate in the Austrian screening program, even a negative benefit-harm balance seems possible. However, with the implementation of quality standards in breast cancer screening and the dissemination of a patient information leaflet, an improvement in the medical treatment situation, specifically in terms of informed decision-making, can be expected.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen - Volume 109, Issues 4–5, 2015, Pages 363-370
نویسندگان
, , , , ,